Navigation Links
CVBT Shareholders Vote for Change
Date:6/8/2013

LAS VEGAS, June 9, 2013 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (CVBT) announced today that its shareholders have voted by over 60% to amend the bylaws of CVBT, remove specific directors of the Company and authorize the remaining directors to consider a financing proposal. 

The board members who have been removed effective June 7, 2013 are Daniel C. Montano, John (Jack) Jacobs, Ernest C. Montano, Viktoriya T. Montano, Ernest Montano III, and Joong Ki Baik.

The remaining two directors, Mickael A. Flaa and Grant Gordon, have appointed three new directors to the CVBT Interim Board of Directors: Calvin A. Wallen III, Jon Ross, and Robert Schleizer. The new directors bring financial, legal, securities and turnaround experience to CVBT's Board.

The Interim Board has met and ratified the bylaw amendments approved by the shareholders, authorized management to consider the financing proposal, terminated prior management and appointed Calvin A. Wallen III as Chairman of the Board, and Mickael A. Flaa as President and CFO.

More information on the new directors will be posted to CVBT's website in the very near future. http://www.cvbt.com 

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to tissue or organs. The company is the sponsor of a Phase II trial to treat severe coronary heart disease (CVBT-141H), and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A Late-Stage trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contacts:
Allison Caplan
CardioVascular BioTherapeutics, Inc.
(702) 839-7200
acaplan@cvbt.com

CVBT Mailing List
To be added to the CVBT Mailing List, please send your contact information to info@cvbtshareholder.com.


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytos Invites to the Annual Shareholders Meeting 2013
2. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
3. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
4. 3SBio Inc. Announces Shareholders Approval of the Amended Merger Agreement
5. Medifirst Solutions, Inc. Announces Update To Shareholders
6. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
7. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
8. Update to Shareholders on Dividend Payment: Medisafe 1 Technologies Corporation Files Corporate Action Form with FINRA for the Dividend Distribution to its Shareholders
9. 3SBio Inc. Announces Receipt of Amended "Going Private" Proposal at $16.70 Per ADS and Intent to Adjourn Extraordinary General Meeting of Shareholders
10. Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
11. 3SBio Inc. Announces Extraordinary General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, announced ... 2016 conference, presented by Joseph Gunnar & Co. ... New York . Nadav Kidron , CEO of ... Presentation Details:   PIONEERS 2016, presented ...
Breaking Medicine Technology:
(Date:4/29/2016)... Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... us. An effective way to confront and deal with these stressors is to adopt ... bad to be good for you. Risa Groux, a certified Holistic Nutritionist and the ...
(Date:4/29/2016)... ... , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite ... a light breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers ... and 1-mile walk were held to increase awareness about Lyme disease and to ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... ... 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali ... way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution ... involves one or both jaw bones. This surgery is performed to correct the alignment of ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Regenerative Medicine ... Places to Work employee satisfaction survey, earning them second place for Tampa’s Best Places ... 25-49 employees. , “This is a great accomplishment for our team,” says RMS ...
Breaking Medicine News(10 mins):